Remedy Biologics

Remedy Biologics is an early-stage, private biotech leveraging a platform for ultra-high throughput discovery by mapping cell function from patient samples, with a core focus on immune biology. The company is led by a seasoned team with deep experience in genomics, data science, and biotech entrepreneurship, including co-founder Dan Crowley. While currently pre-revenue and pre-clinical, its strategy is to build transformational industry partnerships to translate its discovery platform into novel therapies for complex diseases.

Ultra-high throughput therapeutic discovery platform based on mapping the function of cells directly from patient biology, with a focus on deciphering immune biology to identify novel targets and small molecule therapies.

RemedyBio competes in the broad field of AI/ML-driven and high-throughput drug discovery, facing competition from both specialized platform biotechs (e.g., Recursion, Exscientia, Insitro) and internal efforts at large pharma. Its differentiation hinges on its specific approach of patient-derived, functional immune cell mapping.